August 12, 2023

To

To

Listing Department,

The Corporate Relations Department

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

BSE LIMITED

Exchange Plaza,

Phiroz Jeejeebhoy Towers,

Bandra Kurla Complex, Bandra (E),

25th floor, Dalal Street,

MUMBAI -400 051

MUMBAI -400 001

Company Code No. AUROPHARMA

Company Code No. 524804

Dear Sir,

Sub: Press Release on Unaudited Financial Results of the Company for the first quarter ended June 30, 2023.

We enclose a copy of the Press Release on Unaudited Financial Results of the Company for the first quarter ended June 30, 2023.

Please take the information on record.

Yours faithfully,

For AUROBINDO PHARMA LIMITED

Digitally signed by ADIREDDY BADDIGAM

Date: 2023.08.12 18:20:03 +05'30'

B. Adi Reddy

Company Secretary

Encl.: As above

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad - 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: PlotNo. 2, Maithrivihar, Ameerpet, Hyderabad - 500038 T.S., INDIA Tel:+91 402373 6370/ 23747340 Fax: +914023741080/ 23746833 Email: info@aurobindo.com Website: www.aurobindo.com

AUROBINDO PHARMA LIMITED

Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,

Hyderabad Knowledge City, Raidurg Panmaktha,

Hyderabad - 500 032. Telangana, India

Investor Relations | Corporate Communications

Press ReleasePhone: 040-66725401 / 66725000

Email: ir@aurobindo.com

Hyderabad, India, August 12th, 2023: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo") today announced its consolidated financial results for the quarter ended June 30, 2023.

Aurobindo Pharma Ltd. Q1FY24 Consolidated Financial Results

Amount (INR Cr)

Q1FY24

Q1FY23

% Change YoY

Q4FY23

  • Change QoQ

Revenue from operations

6,850.5

6,235.9

9.9%

6,473.0

5.8%

EBITDA before Forex and Other Income

1,151.4

964.7

19.3%

1002.2

14.9%

EBITDA margin (%)

16.8%

15.5%

134 bps

15.5%

132 bps

EBITDA before R&D

1,539.0

1,274.8

20.7%

1,412.9

8.9%

EBITDA margin before R&D (%)

22.5%

20.4%

202 bps

21.8%

64 bps

PBT before share of P/L of JV, Forex, and Exceptional items

846.9

711.2

19.1%

713.3

18.7%

Net Profit after Share of Profit/Loss of JV and minority interest

570.8

520.5

9.7%

505.9

12.8%

Key highlights of Q1FY24

  • Revenue from Operations at INR 6,850.5 Cr increased by 9.9% YoY
  • US formulations revenue increased by 11.2% YoY to INR 3,304 Cr
  • Europe formulation revenue stood at INR 1,837 Cr, with an increase of 18.6% YoY
  • Growth Markets revenue grew by 12.9% YoY to INR 486 Cr
  • ARV revenue stood at INR 190 Cr
  • API revenue grew by 14.0% YoY to INR 1,033 Cr
  • EBITDA before Forex and Other income stood at INR 1,151.4 Cr; EBITDA margin for the quarter was 16.8%.
  • Research & Development (R&D) spend at INR 387.6 Cr, 5.7% of revenues (Q4 FY23: 6.3%)
  • Received final approval for 19 ANDAs including 7 injectable products from the USFDA
  • Net Profit after Share of Profit/Loss of JV and minority interest stood at INR 570.8 Cr, as against INR 520.5 Cr in Q1FY23
  • Basic & Diluted EPS is INR 9.74 per share.

Commenting on the Company's performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: "We are pleased to start the new financial year on a good note with strong top-linegrowth and margin expansion aided by improved performance across our key markets. With our product pipeline continuing to advance, and execution of growth drivers proceeding as planned, we are confident that our fundamental strengths position us to create an upward trajectory. Looking ahead, we are confident in executing our growth initiatives and creating long-termvalue for our shareholders."

AUROBINDO PHARMA LIMITED

Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,

Hyderabad Knowledge City, Raidurg Panmaktha,

Hyderabad - 500 032. Telangana, India

Operational Performance (Consolidated)

Amount (INR Cr)

Q1FY24

Q1FY23

% Change YoY

Q4FY23

% Change QoQ

Formulations

USA

3,304

2,971

11.2%

3,045

8.5%

Europe

1,837

1,548

18.6%

1,660

10.6%

Growth Markets*

486

431

12.9%

592

-17.9%

ARV

190

380

-49.9%

159

19.6%

Total Formulations

5,817

5,329

9.2%

5,456

6.6%

Active Pharmaceutical Ingredients (API)

Betalactam

719

551

30.4%

638

12.8%

Non Betalactam

314

355

-11.5%

380

-17.3%

Total API

1,033

907

14.0%

1,017

1.6%

Consolidated Gross Sales (incl. service

6,851

6,236

9.9%

6,473

5.8%

income)

Dossier Income

0

0

-

0

-

Revenue from operations

6,851

6,236

9.9%

6,473

5.8%

*includes domestic formulation sales of INR 52.4 Cr in Q1 FY24

Q1FY24: Consolidated revenue breakup - Geography & Segment wise

Q1FY24

Domestic,

11%

API, 15.1%

ARV, 2.8%

Growth

Markets,

7.1%

Europe,

International,

26.8%

US, 48.2%

89%

Domestic

International

US

Europe

Growth Markets

ARV

API

AUROBINDO PHARMA LIMITED

Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,

Hyderabad Knowledge City, Raidurg Panmaktha,

Hyderabad - 500 032. Telangana, India

Formulations

For the quarter, Formulation revenue increased by 9.2% YoY to INR 5,817 Cr

US Formulations

  • In Q1 FY24, US revenue increased by 11.2% YoY to INR 3,304 Cr and accounted for 48.2% of consolidated revenues.
  • Filed 12 ANDAs including 1 Injectable product with USFDA in Q1 FY24
  • Received final approval for 19 ANDAs including 7 injectable products in Q1 FY24
  • As on 30th June 2023, on a cumulative basis, the company has filed 814 ANDAs with USFDA and received 613 final approval and 34 tentative approval
  • The company has launched 15 products during the quarter including 5 injectables.

Europe Formulations

  • Europe revenue in Q1 FY24 increased by 18.6% YoY at INR 1,837 Cr. Europe Formulations accounted for 26.8% of consolidated revenue. In Euro terms, Europe revenue increased by 8.8% YoY to EUR 205.4 million.

ARV Formulations

  • ARV business revenue for Q1 FY24 stood at INR 190 Cr, accounting for 2.8% of total revenue.

Growth Markets Formulations

  • Revenue from Growth Markets formulations in Q1 FY24 posted a growth of 12.9% YoY to INR 486 Cr and accounted for 7.1% of revenue. Domestic formulation sales in Q1 FY24 was INR 52.4 Cr.

Active Pharmaceutical Ingredients (API)

  • In Q1 FY24, API business stood at INR 1,033 Cr, increased by 14.0% YoY and contributed 15.1% to the consolidated revenue.

Global Regulatory Filings

Details

ANDAs (including filings from Aurobindo USA)

DMFs (including filings from Eugia and Auro Peptides)

Formulations Dossiers in other key advanced markets (incl. multiple registrations in Europe, South Africa and Canada)

API filings in other key regulated markets (incl. multiple registrations)

Q1FY24

Cumulative Filings as on

30th June 2023

12

814

-

276

12

4,443

-

3,730

AUROBINDO PHARMA LIMITED

Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,

Hyderabad Knowledge City, Raidurg Panmaktha,

Hyderabad - 500 032. Telangana, India

Final USFDA Approvals Received in Q1 FY24

#

Product

Therapy

1

Apixaban Tablets, 2.5 mg and 5 mg

Cardiovascular

2

Alcaftadine Ophthalmic Solution, 0.3%

Anti Histamine

3

Macitentan Tablets, 10 mg

Cardiovascular

4

Methylprednisolone Acetate Injectable Suspension USP, 400 mg/10 mL & 400 mg/5 mL

Anti Inflammatory

5

Nitrofurantoin Oral Suspension USP, 25mg/5 mL

Anti Infective

6

Omeprazole Delayed-Release Capsules (OTC), 20 mg

Gastrointestinal

7

Roflumilast Tablets, 500 mcg

Anti Inflammatory

8

Fexofenadine Hydrochloride Oral Suspension (OTC), 30 mg/5 mL

Anti Histamine

9

Bendamustine Hydrochloride Injection, 100 mg/4 mL (25 mg/mL) [Multiple-Dose Vial]

Anti Neoplastic

10

Estradiol and Norethindrone Acetate Tablets USP, 1 mg/0.5 mg and 0.5 mg/0.1 mg

Hormonal

11

Cevimeline Hydrochloride Capsules, 30 mg

Prosecretory (Cholinergic Agonist)

12

Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) [Single-Dose Prefilled Syringe]

Antiestrogen

13

Phenoxybenzamine Hydrochloride Capsules USP, 10 mg

Cardiovascular

14

Safinamide Tablets, 50 mg and 100 mg

Central Nervous System

15

Tirofiban Hydrochloride Injection, 5 mg/100 mL (50 mcg/mL) and 12.5 mg/250 mL (50

Antiplatelet

mcg/mL) [Single-Dose Flexible Container]

16

Carboprost Tromethamine Injection USP, 250 mcg/mL [Single-Dose Vial]

Oxytocic Agent

17

Rufinamide Tablets USP, 200 mg and 400 mg

Central Nervous System

18

Tobramycin for Injection USP, 1.2 g/Vial [Pharmacy Bulk Package]

Aminoglycoside Antibacterial

19

Posaconazole Injection, 300 mg/16.7 mL (18 mg/mL), Single-Dose Vial

Anti Fungal

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Aurobindo Pharma Ltd. published this content on 12 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 August 2023 08:24:06 UTC.